CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
CYDY(CYDY) VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a change of time for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, to Wednesday, September 10, at 9 a.m. EDT.
CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CYDYVANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City.
A Penny Stock To Watch In Challenging Cancer Space
CYDYThe author has a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 months, representing significant upside from its current price of around $0.32.
